Megan D. Bailey serves as Executive Vice President and President of Central Laboratories and International at LabCorp Holdings Inc., where she leads the company's global central laboratory network and international operations. With over 20 years of experience in the diagnostics and healthcare industry, Bailey joined LabCorp in 2010, rising through senior leadership roles including President of Specialty Testing and Vice President of Operations. Prior to LabCorp, she held progressive positions at Quest Diagnostics and Covance, honing her expertise in laboratory management, regulatory compliance, and strategic growth in complex, high-volume testing environments. She holds a Bachelor of Science in Biology from the University of North Carolina at Chapel Hill and an MBA from Duke University's Fuqua School of Business. Under Bailey's leadership, LabCorp's Central Laboratories have expanded to serve more than 110 countries, supporting pivotal clinical trials for pharmaceutical and biotech partners worldwide. Her strategic initiatives have driven significant revenue growth, with international operations increasing by over 40% in the past five years through investments in advanced automation, digital integration, and capacity enhancements. Bailey's achievements include spearheading the development of LabCorp's Specialty Testing Group, which now generates billions in annual revenue, and earning industry recognition such as the 2022 Healthcare Businesswomen's Association Rising Star Award for her commitment to innovation and diversity in STEM leadership. Bailey continues to champion LabCorp's mission of advancing health insights, fostering partnerships that accelerate drug development and improve patient outcomes globally. Her visionary approach positions the company at the forefront of precision medicine, ensuring operational excellence amid evolving regulatory and technological landscapes.